Home Business U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder

U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder

1 min read
Comments Off on U.S. FDA approves Bluebird bio’s gene therapy for a rare neurological disorder
0
27


Article content

Sept 16 – The U.S. Food and Drug Administration has approved bluebird bio’s gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.

“SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys” with early, active Cerebral Adrenoleukodystrophy (CALD), the company said in a statement, saying CALD is a “devastating and fatal neurodegenerative disease.”

Article content

(Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)



Source link

Load More Related Articles
Load More By 
Load More In Business
Comments are closed.

Check Also

year JGB yield falls, longer-term notes keep rising

Article content TOKYO — The Japanese government bond market moved in mixed directions on W…